[go: up one dir, main page]

DK0498851T3 - Tumorassocieret urinantigen, anvendelse af antigene underenheder og fremgangsmåder til detektion - Google Patents

Tumorassocieret urinantigen, anvendelse af antigene underenheder og fremgangsmåder til detektion

Info

Publication number
DK0498851T3
DK0498851T3 DK90917644.8T DK90917644T DK0498851T3 DK 0498851 T3 DK0498851 T3 DK 0498851T3 DK 90917644 T DK90917644 T DK 90917644T DK 0498851 T3 DK0498851 T3 DK 0498851T3
Authority
DK
Denmark
Prior art keywords
tumor
methods
detection
associated urinary
antigenic subunits
Prior art date
Application number
DK90917644.8T
Other languages
Danish (da)
English (en)
Inventor
Donald L Morton
Rishab K Gupta
David M Euhus
Original Assignee
Donald L Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23712351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0498851(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Donald L Morton filed Critical Donald L Morton
Application granted granted Critical
Publication of DK0498851T3 publication Critical patent/DK0498851T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK90917644.8T 1989-11-03 1990-10-31 Tumorassocieret urinantigen, anvendelse af antigene underenheder og fremgangsmåder til detektion DK0498851T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43153389A 1989-11-03 1989-11-03

Publications (1)

Publication Number Publication Date
DK0498851T3 true DK0498851T3 (da) 1996-05-13

Family

ID=23712351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90917644.8T DK0498851T3 (da) 1989-11-03 1990-10-31 Tumorassocieret urinantigen, anvendelse af antigene underenheder og fremgangsmåder til detektion

Country Status (10)

Country Link
US (2) US5993828A (fr)
EP (2) EP0678744B1 (fr)
JP (2) JP3423306B2 (fr)
AT (2) ATE184704T1 (fr)
AU (1) AU661816B2 (fr)
CA (2) CA2072620C (fr)
DE (2) DE69033295T2 (fr)
DK (1) DK0498851T3 (fr)
ES (2) ES2138102T3 (fr)
WO (1) WO1991006866A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044421C (fr) * 1990-11-27 2005-06-21 Thomas Hyatt Duffy Antigene immunoreactif isole dans l'urine de la femme qui ressemble a l'antigene associe a l'epithelioma spinocellulaire
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9806104D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
JP2003535824A (ja) 2000-04-28 2003-12-02 シーティーエル イムノセラピーズ コーポレーション 抗原提示細胞におけるエピトープ同調
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
EP1752160A3 (fr) 2001-04-06 2007-05-30 Mannkind Corporation Sequences d'epitopes
AU2002327037A1 (en) 2001-09-20 2003-04-01 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
WO2003052144A1 (fr) * 2001-12-14 2003-06-26 Cygene, Inc. Essais diagnostiques pour bcwa
CA2496888A1 (fr) * 2002-09-06 2004-03-18 Mannkind Corporation Sequences de sites antigeniques
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
EP1835932A2 (fr) * 2004-12-29 2007-09-26 Mannkind Corporation Methodes de declenchement, d'accentuation et de maintien de reponses immunitaires contre des epitopes restreints du cmh de classe i a des fins prophylactiques ou therapeutiques
EP2010216A4 (fr) * 2006-03-24 2010-06-09 Donald L Morton Immunotherapie mycobacterienne destinee au traitement du cancer
MX2009001070A (es) * 2006-07-28 2009-04-23 Novartis Ag Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
WO2015089268A1 (fr) 2013-12-11 2015-06-18 University Of Massachusetts Compositions et procédés de traitement d'une maladie au moyen d'une protéine effectrice t3ss de salmonella (sipa)
US20210012858A1 (en) 2018-03-16 2021-01-14 Kotai Biotechnologies, Inc. Effective clustering of immunological entities
WO2025054471A1 (fr) * 2023-09-08 2025-03-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Procédés et matériels pour évaluer et traiter des cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603406A (en) * 1977-08-31 1981-11-25 Nat Res Dev Assay of immune complexes
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5915858A (ja) * 1982-07-16 1984-01-26 Otsuka Pharmaceut Co Ltd 腫瘍関連抗原特異的免疫複合体の測定法
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4562160A (en) * 1983-04-01 1985-12-31 Sloan-Kettering Institute Melanoma tumor antigen and autologous antibody
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4753884A (en) * 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
GB2188637B (en) * 1986-02-07 1990-11-14 Oncogen Vaccines against melanoma
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US4895817A (en) * 1986-05-09 1990-01-23 The Goodyear Tire & Rubber Company Polycondensation catalyst
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy
US5250297A (en) * 1989-10-20 1993-10-05 Hybritech Incorporated Tumor-associated antigen, antibodies, compositions and uses therefor
US5427664A (en) * 1993-07-22 1995-06-27 Stoev; Stoyan V. Free solution electrophoresis-membrane filters trapping assay apparatus and method
DK0668350T4 (da) * 1994-02-16 2009-02-23 Us Gov Health & Human Serv Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom

Also Published As

Publication number Publication date
CA2072620C (fr) 2007-06-12
EP0498851A1 (fr) 1992-08-19
WO1991006866A2 (fr) 1991-05-16
EP0498851B1 (fr) 1996-01-03
ES2084715T3 (es) 1996-05-16
JPH05505596A (ja) 1993-08-19
DE69033295D1 (de) 1999-10-21
DE69024659D1 (de) 1996-02-15
WO1991006866A3 (fr) 1991-09-05
US5700649A (en) 1997-12-23
US5993828A (en) 1999-11-30
EP0678744B1 (fr) 1999-09-15
JP2001281255A (ja) 2001-10-10
EP0678744A2 (fr) 1995-10-25
DE69033295T2 (de) 2000-05-25
JP3429281B2 (ja) 2003-07-22
DE69024659T2 (de) 1996-11-07
CA2331088A1 (fr) 1991-05-04
ES2138102T3 (es) 2000-01-01
ATE132629T1 (de) 1996-01-15
ATE184704T1 (de) 1999-10-15
CA2072620A1 (fr) 1991-05-04
AU661816B2 (en) 1995-08-10
AU6875391A (en) 1991-05-31
EP0678744A3 (fr) 1995-12-13
JP3423306B2 (ja) 2003-07-07

Similar Documents

Publication Publication Date Title
DK0498851T3 (da) Tumorassocieret urinantigen, anvendelse af antigene underenheder og fremgangsmåder til detektion
DK174416B1 (da) Oligopeptider, immunogene konjugater heraf med et antigen samt vacciner indeholdende disse konjugater
NO870412L (no) Peptider.
DK162056C (da) Anti-tumor, anti-idiotype-antistof til induktion af immunologisk respons
DK120383D0 (da) Fremgangsmade til fremstilling af konjugater af haptener og muramylpeptider, der har immunogen virkning
FI864991A0 (fi) Expression och diagnostisk anvaendning av peptider kodade av gag-region vilka peptider aer immunologiskt reaktiva med antikroppar av lav-virus.
DK162467C (da) Immunoanalyse og fremgangsmaade til paavisning af antistof mod hepatitis b overfladeantigen/a
ATE242784T1 (de) Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis
NO174153C (no) Antigen og monoklonalt antistoff for anvendelse in vitro, samt immunologiske reagenser inneholdende disse
DK218886D0 (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
ATE144146T1 (de) Gentechnologisch hergestellter coccidiose- impfstoff
DK314886A (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
FI854839L (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
DK142488A (da) Treponema hyodysenteriae antigener, vaccine indeholdende disse antigener eller fragmenter deraf og metode til bestemmelse af antistoffer over for treponema hyodysenteriae
DE69026076D1 (de) Exkretorische/sekretorische antigene des bandwurms (cysticercus cellulosae) zur verwendung in der immundiagnostik und der impfstoffbereitung
WO1990015132A3 (fr) Gene endoflagellaire clone de treponema hyodysenteriae
GR1001087B (el) Μεθοδος και συστηματα για τον προσδιορισμο της παρουσιας ενος αντιγονου του pneumocystis carinii στο αιμα